ProCE Banner Activity

My Take on Personalizing First-line Treatment for Patients With CLL

Clinical Thought
How can clinicians best leverage targeted agents to personalize first-line treatment of patients with CLL? Here’s how I individualize therapy based on important factors such as age, comorbidities, presence of del(17p)/TP53 mutation, and IGHV mutation status.

Released: October 22, 2020

Expiration: October 21, 2021

No longer available for credit.

Share

Faculty

William G. Wierda

William G. Wierda, MD, PhD

Associate Professor of Medicine
Department of Leukemia
The University of Texas
M.D. Anderson Cancer Center
Houston, Texas

Provided by

Provided by National Comprehensive Cancer Network, in partnership with Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca Pharmacyclics AbbVie

Janssen administered by Scientific Affairs

Lilly

Faculty Disclosure

Primary Author

William G. Wierda, MD, PhD

Associate Professor of Medicine
Department of Leukemia
The University of Texas
M.D. Anderson Cancer Center
Houston, Texas

William G. Wierda, MD, PhD, has disclosed that he has received funds for research support from AbbVie, Acerta, Cyclacel, Genentech, Gilead Sciences, Janssen, Juno, Kite, Loxo, miRagen, Novartis, Oncternal, Pharmacyclics, Sunesis, and Xencor.